Enveric Biosciences Inc. (ENVB) reported new mechanistic data from proprietary bioluminescence resonance energy transfer (BRET) assays demonstrating that its lead candidate, EB-003, activates both Gq-and ß-arrestin-mediated signaling downstream of the 5-HT A receptor. Independent peer-reviewed studies have linked selective activation of these pathways to antidepressant- and anxiolytic-like effects in preclinical models, suggesting therapeutic benefit can arise from either mechanism.
Enveric's data further indicated that EB-003 shows a modest preference toward ß-arrestin signaling relative to serotonin, the receptor's native ligand.
A recent Nature study provided additional clarity, reporting that Gi signaling downstream of 5-HTA was required for hallucinogenic effects, while Gq signaling mediated antidepressant- and anxiolytic-like benefits. These findings support Enveric's strategy of developing non-hallucinogenic neuroplastogens designed to deliver therapeutic benefit without the safety and scalability constraints of psychedelic compounds.
"Growing mechanistic clarity around 5-HTA signaling strengthens confidence in the scientific foundation of our platform," said Joseph Tucker, CEO of Enveric Biosciences. He added that EB-003 is being advanced through IND-enabling studies, with additional BRET testing planned to further characterize its unique signaling profile.
EB-003 is intended to be a non-hallucinogenic neuroplastogen that could support streamlined treatment paradigms, including potential at-home administration. The company continues to progress toward clinical development.
The company implemented a 1-for-12 reverse stock split on October 28, 2025.
ENVB is currently trading at $2.40 up 7%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.